Dan Peizer Reveals Catalant’s Newest Acquisition

Bioprocessing

Bioprocessing and Capacity Trends: Growth Despite Continued Uncertainty

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Formulation Models

Predictive Formulation: Can Modeling Reduce Empirical Development?

David Alvaro, Ph.D.

Pharma's Almanac

LNP Analytics

Beyond Particle Size: Building a Complete Analytical Strategy for LNPs

Pharma's Almanac

Nonviral Delivery

Can Nonviral Delivery Change the Economics of Gene Therapy?

David Alvaro, Ph.D.

Pharma's Almanac

Viral Vectors

Gene Therapy Manufacturing After the Capacity Boom

David Alvaro, Ph.D.

Pharma's Almanac

New Technology

What are the key bottlenecks preventing rapid adoption of novel technologies?

Pharma's Almanac

Heme-Onc

Therapeutic and Diagnostic Advances Benefiting Patients with Hematologic Malignancies

Cynthia A. Challener, Ph.D.

Pharma's Almanac

DS + DP Integration

Integrating Drug Substance and Drug Product to Reduce Risk Across Development

Dörthe Ackenhausen

IDT Biologika

Multi-Modality CDMO

The Rise of the Multi-Modality CDMO: Why Clients Need More Than Capacity

Kamal Preet

OneSource Specialty Pharma

Heme-Onc

The Next Generation of Targeted Therapies in Hematologic Malignancies

DDC Development

Building Better Combination Products by Engaging Device Development Earlier

Loganathan S.

OneSource Specialty Pharma